Manufacturer of Controlled Substances; Notice of Application, 56612 [E8-22874]
Download as PDF
<![CDATA[
56612
Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be
filed no later than October 29, 2008.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedules I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22873 Filed 9–26–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 24, 2008,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
to the Drug Enforcement Administration
(DEA) as a bulk manufacturer of
Gamma-Hydroxybutyric acid (2010), a
basic class of controlled substance listed
in schedule I.
The company plans on producing
sodium oxybate for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
VerDate Aug<31>2005
16:48 Sep 26, 2008
Jkt 214001
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 28, 2008.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22874 Filed 9–26–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22876 Filed 9–26–08; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
By Notice dated May 19, 2008 and
published in the Federal Register on
May 27, 2008 (73 FR 30418), AMRI
Rensselaer, Inc., 33 Riverside Avenue,
Rensselaer, New York 12144, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule I and II:
DEPARTMENT OF JUSTICE
Drug
Schedule
Marihuana (7360) ..........................
Tetrahydrocannabinols (7370) ......
Amphetamine (1100) .....................
Lisdexamfetamine (1205) ..............
Methylphenidate (1724) ................
Pentobarbital (2270) ......................
Hydrocodone (9193) .....................
Meperidine (9230) .........................
Dextropropoxyphene, bulk (nondosage form) (9273).
Oxymorphone (9652) ....................
Fentanyl (9801) .............................
I
I
II
II
II
II
II
II
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
AMRI Rensselaer, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated AMRI Rensselaer, Inc. to
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 3, 2008 and
published in the Federal Register on
June 10, 2008 (73 FR 32736), Cambrex
Charles City, Inc., 1205 11th Street,
Charles City, Iowa 50616, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Phenylacetone for use as a precursor in
the manufacture of amphetamine only.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Cambrex Charles City, Inc. to import the
basic class of controlled substance is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Cambrex Charles City, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 73, Number 189 (Monday, September 29, 2008)]
[Notices]
[Page 56612]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-22874]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 24, 2008, Johnson
Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West
Deptford, New Jersey 08066-1742, made application by letter to the Drug
Enforcement Administration (DEA) as a bulk manufacturer of Gamma-
Hydroxybutyric acid (2010), a basic class of controlled substance
listed in schedule I.
The company plans on producing sodium oxybate for sale to its
customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than November 28, 2008.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-22874 Filed 9-26-08; 8:45 am]
BILLING CODE 4410-09-P
